Document is current
Any future updates will be listed below
-
Authors
Park, Seonghyeon
Kwon, Ohman https://orcid.org/0000-0002-4744-5360
Lee, Hana https://orcid.org/0000-0001-7782-5711
Cho, Younghak
Yeun, Jemin
Yoon, Sung Hyun
Sun, Sang Yu
Huh, Yubin
Yu, Won Dong
Park, Sohee
Son, Naeun
Jeon, Sojeong
Lee, Sugi
Kim, Dae-Soo https://orcid.org/0000-0002-4999-1613
Lee, Sun Young https://orcid.org/0000-0002-6568-9377
Son, Jin Gyeong
Lee, Kyung Jin
Kim, Yong Il https://orcid.org/0000-0003-1503-365X
Lim, Jin Hong
Yoo, Jongman
Lee, Tae Geol
Son, Mi-Young https://orcid.org/0000-0001-7590-8812
Im, Sung Gap https://orcid.org/0000-0002-2802-6398
- License Information
-
More Information
Article History
Received: 6 March 2024
Accepted: 18 November 2024
First Online: 2 December 2024
Competing interests
: The authors declare no competing interests.
: This study complies with all relevant ethical regulations. All studies based on human pluripotent stem cells were approved by the Korean Public IRB (IRB number: P01-201409-ES-01-09, P01-201609-31-002). Male NIG mice (Nod/scid-IL2Rg<sup>em1</sup>/GH, 6–12 weeks old; GHBio, Daejeon, Korea) were housed in a specific pathogen-free facility with a controlled 12-hour light/dark cycle, temperature maintained at 20-22 °C, and relative humidity at 55 ± 5%. The mice were provided with ad libitum access to water and fed a purified AIN-76A diet (Teklad Custom Research Diet, CA.170481; Envigo, Indianapolis, IN, USA). All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of KRIBB (KRIBB-AEC-22233). For the study based on human blood, informed consent was obtained prior to participation with approval from the IRB at Yonsei University Health System (IRB No. 3-2023-0347).
